Kim's Eye Hospital
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1962-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://kimeye.com
Clinical Trials
8
Active:0
Completed:6
Trial Phases
2 Phases
Phase 4:4
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 4
4 (80.0%)Not Applicable
1 (20.0%)Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
Phase 4
Recruiting
- Conditions
- Age-related Macular Degeneration (ARMD)
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06683950
- Locations
- 🇰🇷
Kim's Eye Hospital, Seoul, Korea, Republic of
Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV
Completed
- Conditions
- Polypoidal Choroidal VasculopathyChoroidal NeovascularizationAge-Related Macular Degeneration
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 135
- Registration Number
- NCT05662943
- Locations
- 🇰🇷
Jae Hui Kim, Seoul, Korea, Republic of
Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy
Phase 4
Completed
- Conditions
- Pachychoroid Neovasculopathy
- Interventions
- Drug: Three monthly injections of intravitreal aflibercept
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05662410
- Locations
- 🇰🇷
Jae Hui Kim, Seoul, Korea, Republic of
Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion
Completed
- Conditions
- Age-related Macular Degeneration
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 512
- Registration Number
- NCT04836143
- Locations
- 🇰🇷
Jae Hui Kim, Seoul, Korea, Republic of
Treat-and-extend Using Aflibercept for Type 3 Neovascularization
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Kim's Eye Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04655482
- Locations
- 🇰🇷
Jae Hui Kim, Seoul, Korea, Republic of
- Prev
- 1
- 2
- Next
News
No news found